A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy

Cancer Research

Volumn 61, Issue 20, 2001, Pages 7464-7472

  DeWeese, Theodore L ^a,b   van der Poel, Henk ^a   Li, Shidong ^a   Mikhak, Bahar ^a   Drew, Renee ^a   Goemann, Marti ^a   Hamper, Ulrike ^b   DeJong, Robert ^b   Detorie, Nicholas ^a   Rodriguez, Ronald ^c   Haulk, Thomas ^a   DeMarzo, Angelo M ^b   Piantadosi, Steven ^a   Yu, D C ^d   Chen, Yu ^d   Henderson, Daniel R ^d   Carducci, Michael A ^a,c   Nelson, William G ^a,c   Simons, Jonathan W ^a,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c Calydon Inc ^*

^d Calydon Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CV 706; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG MEGADOSE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER FUNCTION TEST; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY TRACT DISEASE; UROGENITAL TRACT DISEASE; VIRUS REPLICATION; VIRUS SHEDDING;

ADENOVIRIDAE; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; BIOPSY; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0035887153     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis
2. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness
3. The significance of post-irradiation prostate biopsy with long-term follow-up
4. 125I implantation
5. Viruses in the treatment of cancer
6. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression
7. The use of DNA viruses as vectors for gene therapy
8. Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: Implications for prognosis and response to endocrine therapy
9. Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing
10. A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
11. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A Phase II trial
12. Studies on the use of viruses in the treatment of carcinoma of the cervix
13. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
14. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
15. The development of conditionally replicative adenoviruses for cancer therapy
16. Pathological features of hereditary prostate cancer
17. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma
18. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: The Columbia experience
19. Salvage radical prostatectomy: Outcome measured by serum prostate specific antigen levels
20. Permanent brachytherapy as salvage treatment for recurrent prostate cancer
21. Salvage brachytherapy for localized prostate cancer after radiotherapy failure
22. Consensus statement: Guidelines for PSA following radiation therapy
23. "Sero-switch" adenovirus-mediated in vivo gene transfer: Circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype
24. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
25. A Phase II trial of intratumoral injection with an E1B-deleted adenovirus, onyx-015, in patients with recurrent, refractory head and neck cancer
26. The role of IL-6 in the inflammatory and humoral response to adenoviral vectors
27. Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain
28. Cytokines in adenoviral disease in children: Association of interleukin-6, interleukin-8, and tumor necrosis factor α levels with clinical outcome
29. Prostate specific antigen: A decade of discovery - What we have learned and where we are going
30. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
31. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
32. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer
33. Natural history of progression after PSA elevation following radical prostatectomy
34. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels
35. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy
36. Biodistribution of monoclonal antibodies: Scale-up from mouse to human using a physiologically based pharmacokinetic model
37. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene
38. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
39. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel
40. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity